Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | SQLE | Q14534 | 3/20 | 0.53 |
| ▸ | FNTA | P49354 | 4/20 | 0.53 |
| ▸ | FNTB | P49356 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15370334 | 1.00 | KMT2A (0.61) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL6442169 | 1.00 | KMT2A (0.61) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL14077034 | 1.00 | KMT2A (0.61) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL6442176 | 1.00 | KMT2A (0.61) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL560299 | 0.98 | ALOX15 (0.58) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL358273 | 0.98 | ALOX15 (0.58) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| SCHEMBL560298 | 0.98 | ALOX15 (0.58) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| Water SCHEMBL9744752 | 0.96 | ALOX15 (0.56) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| Ether SCHEMBL9744748 | 0.92 | ALOX15 (0.56) | KMT2AALOX15ALDH1A1MAPTMEN1 | |
| Nerol SCHEMBL458984 | 0.91 | ALOX15 (0.68) | KMT2AALOX15ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100021412-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY, A DELAWARE CORPORATION | 2010-01-28 | — | — | US | claimed |
| CN-101184532-A | Reduction of hair growth | GILLETTE CO (US) | 2008-05-21 | — | — | CN | claimed |
| US-20060269496-A1 | Reduction of hair growth | GILLETTE COMPANY, THE | 2006-11-30 | — | — | US | claimed |
| US-20060035873-A1 | Methods for inducing apolipoprotein e secretion | ILEX PRODUCTS, INC. | 2006-02-16 | — | — | US | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| EP-1019059-A4 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | UNIV CALIFORNIA (US) | 2004-01-14 | — | — | EP | claimed |
| EP-1313483-A2 | METHODS FOR INDUCING APOLIPOPROTEIN E SECRETION | SYMPHAR S.A. (CH) | 2003-05-28 | — | — | EP | claimed |
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | MERCK & CO., INC. | 2002-06-27 | — | — | US | claimed |
| WO-2002011708-A2 | METHODS FOR INDUCING APOLIPOPROTEIN E SECRETION | SYMPHAR S.A. (CH) | 2002-02-14 | — | — | WO | claimed |
| JP-2001509165-A | — | — | 2001-07-10 | — | — | JP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| US-6187814-B1 | BY TOPICALLY AN FARNESOID X-ACTIVATED RECEPTOR (FXR) ACTIVATOR SELECTED FROM FARNESAL, ALKYL FARNESYL ETHER, ALKYL FARNESOATE, AND 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID, ALKYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-13 | — | — | US | claimed |
| EP-1019059-A1 | USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1998032444-A1 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-30 | — | — | WO | claimed |
| US-5475029-A | Farnesyl compounds as cholesterol lowering agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-12-12 | — | — | US | claimed |
| EP-2097059-B1 | CLEANSING OR CARE PRODUCT | HENKEL KGAA (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2167018-A2 | COSMETIC STICK BASED ON A CONGEALED OIL-IN-WATER DISPERSION/EMULSION | Henkel AG & Co. KGaA (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-4668705-A | Sebosuppressive preparations containing alkoxyaryl alkanols | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4613622-A | Sebosuppressive preparations containing benzyl alcohol derivatives | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-09-23 | — | — | US | disclosed |
| US-4331655-A | Cosmetic compositions and processes containing ether and acyl derivatives of 3,7,11-trimethyl-2,6,10-dodecatriene-1-ol | UNI-CHEMIE AG (CH) | 1982-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082244-A1 | Compositions and methods for inhibiting bone resorption | SOST, PTEN, ALPI | KMT2A 4503/4885ALOX15 441/4885ALDH1A1 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.